OVDs ideal for microincision surgery

Article

Moderately cohesive ophthalmic viscosurgical devices offer desired performance traits

She presented findings from a study evaluating the OVD behaviour and endothelial cell loss in groups of 20 eyes each operated on using PhysioVisc Integral (PhysIOL, Liège, Belgium), Amvisc Plus (Bausch + Lomb Surgical, Greater London, UK) or Z-Hyalin Plus (Carl Zeiss Meditec, Jena, Germany). All surgeries were performed using the same phacoemulsification platform (Stellaris, Bausch + Lomb) and a bimanual microincision technique involving two 1.2 mm incisions and with enlargement of one incision to 1.7 mm for IOL implantation.

Observations

"When surgeons perform cataract surgery through self-sealing incisions, the OVD is expected to maintain the anterior chamber depth so as to facilitate the capsulorhexis," she explained. "However, while the OVD needs to provide space and tissue protection, if it is not spontaneously expelled during surgical manoeuvers, particularly during hydrodissection, there is a risk of overpressurisation that can lead to capsule rupture.

"The study results show that each of these OVDs offers behaviour that is in line with [the] surgeon's expectations and that the OVDs provided good protection for the corneal endothelium," Dr Deidier added.

As moderately cohesive OVDs, all three products evaluated in the study have high viscosity, strong elasticity and strong pseudoplasticity that allow easy injection through a 27-gauge cannula and removal at the end of the procedure, even with 1.2 mm microincision instruments, noted Dr Deidier.

The three study groups were similar with respect to mean patient age (72 to 76 years), cataract grade (about LOCS III) and preoperative ECC measured by specular microscopy (about 2400 cells/mm2). Based on measurements performed at a month after surgery, mean ECC loss was 1% in eyes operated on with PhysioVisc Integral, 1.09% in the Amvisc Plus group and 1.01% for the Z-Hyalin Plus procedures.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.